A tighter archive for life-science signals.
Search once, then narrow by source or topic.
RION engages Lonza to scale manufacturing exosome based therapeutics - News-Medical
RION engages Lonza to scale manufacturing exosome based therapeutics News-Medical
RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics - Business Wire
RION Engages Lonza to Scale Manufacturing Exosome Based Therapeutics Business Wire
RION Partners with Lonza for Scalable Exosome-Based Drug Manufacturing - Contract Pharma
RION Partners with Lonza for Scalable Exosome-Based Drug Manufacturing Contract Pharma
Lonza Agrees to Scale Manufacturing for RION’s Exosome-Based Therapeutics - GEN - Genetic Engineering and Biotechnology News
Lonza Agrees to Scale Manufacturing for RION’s Exosome-Based Therapeutics GEN - Genetic Engineering and Biotechnology News
Top 10 Contract Development and Manufacturing Organizations 2025 - GEN - Genetic Engineering and Biotechnology News
Top 10 Contract Development and Manufacturing Organizations 2025 GEN - Genetic Engineering and Biotechnology News
Lonza leaders on manufacturing readiness: Meeting the cell and gene therapy challenge - BioSpectrum Asia
Lonza leaders on manufacturing readiness: Meeting the cell and gene therapy challenge BioSpectrum Asia
Lonza Investing in Large-Scale Biomanufacturing, Bioconjugation, Drug-Product Manufacturing - DCAT Value Chain Insights
Lonza Investing in Large-Scale Biomanufacturing, Bioconjugation, Drug-Product Manufacturing DCAT Value Chain Insights
Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure - BioProcess International
Vaxcyte cites manufacturing investments at Lonza facility in Visp as key 2024 expenditure BioProcess International
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page